Concizumab efficacy results at 56-week cut-off in patients with hemophilia A/B without inhibitors: an intra-patient analysis from the phase 3 explorer8 study

Disease Areas
Congresses
Scientific Publications
IME

Register Login

My Account

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

Congresses
ISTH
Concizumab efficacy results at 56-week cut-off in patients with hemophilia A/B without inhibitors: an intra-patient analysis from the phase 3 explorer8 study